Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | PREP | P48147 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656053 | 0.86 | SIGMAR1 (0.66) | SIGMAR1HRH3MEN1ALDH1A1LMNA | |
| SCHEMBL24564680 | 0.83 | HRH3 (0.64) | SIGMAR1HRH3MEN1ALDH1A1LMNA | |
| SCHEMBL24564566 | 0.82 | HRH3 (0.63) | SIGMAR1HRH3MEN1ALDH1A1LMNA | |
| SCHEMBL15314413 | 0.82 | SIGMAR1 (0.73) | SIGMAR1HRH3MEN1ALDH1A1LMNA | |
| SCHEMBL15314418 | 0.82 | SIGMAR1 (0.73) | SIGMAR1HRH3MEN1ALDH1A1LMNA | |
| SCHEMBL10123280 | 0.82 | SIGMAR1 (0.76) | SIGMAR1HRH3PREP | |
| SCHEMBL870758 | 0.82 | SIGMAR1 (0.76) | SIGMAR1HRH3PREP | |
| SCHEMBL24564696 | 0.81 | MEN1 (0.67) | SIGMAR1HRH3MEN1KMT2AAR | |
| SCHEMBL24564633 | 0.81 | SIGMAR1 (0.60) | SIGMAR1HRH3ALDH1A1AR | |
| SCHEMBL24564600 | 0.81 | SIGMAR1 (0.56) | SIGMAR1HRH3MEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140464-A1 | COMPOUNDS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS BY TARGETING HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204471-A1 | Compounds and Methods for Treating Autoimmune Disorders by Targeting HLA-DQ2 | HLA-DRB1, CD74, HLA-B | SIGMAR1 4552/4885HRH3 393/4885MEN1 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.